AUTHORS
Youssef Youssef, MD, Joel Cesar2, Fode Tounkara, PhD3, Luay Mousa, MD4, Elshafa H Ahmed, PhD5, Timothy J Voorhees, MD,MSc6, Walter Hanel, MD, PhD7, Haley Lynn Klimaszewski, BS8, Wing Keung Chan, PhD9, Bethany Mundy-Bosse, PhD10, Lapo Alinari, MD, PhD11, Aharon G Freud, MD, PhD12, Robert A Baiocchi, MD, PhD13
AFFILIATIONS
1 the Ohio State University, Columbus, United States
2 the Ohio State University, Columbus, United States
3 the Ohio State University, Columbus, United States
4 the Ohio State University, Columbus, United States
5 the Ohio State University, Columbus, United States
6 the Ohio State University, Columbus, United States
7 the Ohio State University, Columbus, United States
8 the Ohio State University, Columbus, United States
9 the Ohio State University, Columbus, United States
10 the Ohio State University, Columbus, United States
11 the Ohio State University, Columbus, United States
12 the Ohio State University, Columbus, United States
13 the Ohio State University, Columbus, United States
ABSTRACT
PTLDs are aggressive, often EBV-driven lymphomas arising after organ transplantation under immunosuppression, representing the second most common (~21%) and most lethal post-transplant cancer, with a median overall survival (OS) of approximately 6 months in aggressive subtypes. Six PTLD subtypes are recognized: three nondestructive/early lesions (plasmacytic hyperplasia, florid follicular hyperplasia, and infectious mononucleosis-like), polymorphic, monomorphic, and classic Hodgkin lymphoma-type (cHL). Available treatments, including reduction of immunosuppression, rituximab, R-CHOP, and EBV-specific T-cell therapy, remain limited by organ-rejection risk, variable efficacy, toxicity, cost, and availability. This highlights the need for strategies that restore durable immune surveillance.
Natural killer (NK) cells are essential for early control of EBV-infected B cells post-transplantation. However, ~70% of patients with PTLD exhibit profound NK-cell lymphopenia with skewing toward immature, less cytotoxic NK-cell subsets, potentially permitting EBV-driven B-cell expansion and disease progression. The immunoinhibitory axis, composed of CD200 ligand (CD200) and its inhibitory receptor (CD200R1), is upregulated across multiple malignancies. Previous reports indicate that CD200 expression in PTLD correlates with inferior 5-year OS (29% vs. 78%). Our data show: (1) CD200R1 is selectively expressed on immature NK cells (CD56BrightCD94+CD16?); (2) CD200/CD200R1 engagement impairs NK development into mature subsets (CD56DimCD16+) and suppresses effector function; and (3) CD200R1 acquisition on NK cells is MEK1/2-dependent. Lastly, in our autologous huPBL-SCID PTLD mouse model, CD200 was enriched on lymphoma cells and activated CD4+CD25+ T cells in association with immature NK-cell accumulation. Hypothesis: CD200 within the PTLD microenvironment drives NK-cell dysfunction and lymphopenia, creating a targetable immunosuppressive niche.
We evaluated CD200 expression by immunohistochemistry (IHC) in 33 treatment-naïve PTLD cases including 4 polymorphic, 3 EBV-negative and 13 EBV-positive DLBCLs, 9 primary CNS lymphoma (PCNSL), 2 classic Hodgkin lymphoma-type (cHL), and 2 plasmablastic cases. CD200 was detected in approximately 50% of cases and was significantly higher than in benign lymph nodes and pediatric tonsils with follicular hyperplasia (FH; n=15; median, 3%; p=0.0007). Expression differed across diagnostic categories (p<0.005), with medians of 10% in polymorphic, 5% in EBV-negative DLBCL, 15% in EBV-positive DLBCL, 70% in PCNSL, 90% in cHL-type, and 11.5% in plasmablastic PTLD. CD200 expression on lymphoma cells (>5%) was not associated with differences in OS but was linked to a shorter transplant-to-DLBCL-PTLD diagnosis interval (median time to diagnosis: 5.9 vs. 84.3 months; p=0.004; n=16), suggesting that tumor-cell CD200 may be particularly relevant during early PTLD evolution. Next, because CD200 was also detected on CD4+ T cells in our in vivo model, we examined whether FOXP3+ regulatory T cells (Tregs), key contributors to PTLD immunosuppression, express CD200. Compared with FH controls (n=11; median 0%) and polymorphic PTLD (n=2; median 0%), CD200/FOXP3 co-expression by IHC was increased in monomorphic PTLD (n=15; median 12.5%; p=0.006 vs. FH), including 2 EBV-negative and 4 EBV-positive DLBCL, 7 PCNSL, and 2 plasmablastic cases. Flow cytometry of benign pediatric tonsils confirmed the absence of CD200 on FOXP3+ Tregs. Among 17 evaluable PTLD cases, CD200/FOXP3 co-expression >5% was associated with numerically shorter median OS than co-expression ≤5% (56.3 vs. 138.5 months; p=0.091). This trend, although not statistically significant, suggests that CD200 acquisition on Tregs may better reflect the established immunosuppressive PTLD TME that shapes prognosis and response to treatment. Finally, in an autologous co-culture pairing PBMCs from an EBV-positive donor with the donor-matched CD200? PTLD cell line, NK cells robustly upregulated CD200R1; this was significantly reduced by the MEK1/2 inhibitor mirdametinib, which also decreased tumor-cell counts by ~40%.
Together, our data define the CD200/CD200R1 axis as a novel immunosuppressive pathway whose upregulation may contribute to early post-transplant PTLD evolution and shape post-diagnosis prognosis and treatment response through T/NK-cell dysregulation, supporting therapeutic targeting with CD200R1 blockade (23ME-00610) or MEK1/2 inhibitors.
DISCLOSURES
Youssef Youssef, MD: No relevant conflicts of interest to declare.